Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in silico Liver-to-Plasma Partition Coefficients
In this study, two sets of in silico Kp,h values for 14 model substances were assessed using experimentally reported in vivo steady-state Kp,h data and time-dependent virtual internal exposures in the liver and plasma modeled by forward dosimetry in rats. The Kp,h values for 14 chemicals independently calculated using the primary Poulin and Theil method in this study were significantly correlated with those obtained using the updated Rodgers and Rowland method and with reported in vivo steady-state Kp,h data in rats. When pharmacokinetic parameters were derived based on individual in vivo time-dependent data for diazepam, ...
Source: Biological and Pharmaceutical Bulletin - June 28, 2023 Category: Drugs & Pharmacology Authors: Koichiro Adachi Masayoshi Utsumi Tasuku Sato Hina Nakano Makiko Shimizu Hiroshi Yamazaki Source Type: research
Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in silico Liver-to-Plasma Partition Coefficients
In this study, two sets of in silico Kp,h values for 14 model substances were assessed using experimentally reported in vivo steady-state Kp,h data and time-dependent virtual internal exposures in the liver and plasma modeled by forward dosimetry in rats. The Kp,h values for 14 chemicals independently calculated using the primary Poulin and Theil method in this study were significantly correlated with those obtained using the updated Rodgers and Rowland method and with reported in vivo steady-state Kp,h data in rats. When pharmacokinetic parameters were derived based on individual in vivo time-dependent data for diazepam, ...
Source: Biological and Pharmaceutical Bulletin - June 28, 2023 Category: Drugs & Pharmacology Authors: Koichiro Adachi Masayoshi Utsumi Tasuku Sato Hina Nakano Makiko Shimizu Hiroshi Yamazaki Source Type: research
Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in silico Liver-to-Plasma Partition Coefficients
In this study, two sets of in silico Kp,h values for 14 model substances were assessed using experimentally reported in vivo steady-state Kp,h data and time-dependent virtual internal exposures in the liver and plasma modeled by forward dosimetry in rats. The Kp,h values for 14 chemicals independently calculated using the primary Poulin and Theil method in this study were significantly correlated with those obtained using the updated Rodgers and Rowland method and with reported in vivo steady-state Kp,h data in rats. When pharmacokinetic parameters were derived based on individual in vivo time-dependent data for diazepam, ...
Source: Biological and Pharmaceutical Bulletin - June 28, 2023 Category: Drugs & Pharmacology Authors: Koichiro Adachi Masayoshi Utsumi Tasuku Sato Hina Nakano Makiko Shimizu Hiroshi Yamazaki Source Type: research
The impact of fingolimod on Treg function in brain ischaemia
In conclusion, fingolimod seems to improve the suppressive function of Treg post-stroke while also increasing the resistance of CD4+ effector cells to this suppression. Fingolimod's capacity to increase both effector and regulatory functions may explain the lack of consistent improvement in functional recovery in experimental brain ischaemia.PMID:37366289 | DOI:10.1002/eji.202350370 (Source: European Journal of Immunology)
Source: European Journal of Immunology - June 27, 2023 Category: Allergy & Immunology Authors: Kyle Malone Jennifer A Shearer Christian Waeber Anne C Moore Source Type: research
The impact of fingolimod on Treg function in brain ischaemia
In conclusion, fingolimod seems to improve the suppressive function of Treg post-stroke while also increasing the resistance of CD4+ effector cells to this suppression. Fingolimod's capacity to increase both effector and regulatory functions may explain the lack of consistent improvement in functional recovery in experimental brain ischaemia.PMID:37366289 | DOI:10.1002/eji.202350370 (Source: European Journal of Immunology)
Source: European Journal of Immunology - June 27, 2023 Category: Allergy & Immunology Authors: Kyle Malone Jennifer A Shearer Christian Waeber Anne C Moore Source Type: research
Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review
Hossein Mozhdehipanah, Farshid Safdarian, Sepideh PaybastNeurology India 2023 71(3):546-548
Fingolimod has been approved as a disease-modifying drug in multiple sclerosis since 2010. There are a few reports of melanoma as a side effect of Fingolimod in the literature. Herein we aim to report a known case of multiple sclerosis under Fingolimod presenting with persistent nasal congestion who was eventually diagnosed with soft palate malignant melanoma. (Source: Neurology India)
Source: Neurology India - June 15, 2023 Category: Neurology Authors: Hossein Mozhdehipanah Farshid Safdarian Sepideh Paybast Source Type: research
Fingolimod as a sphingolipid modulator in hepatopulmonary syndrome: a critical review
none (Source: Journal of Hepatology)
Source: Journal of Hepatology - June 8, 2023 Category: Gastroenterology Authors: Sarah Raevens, Michael B. Fallon Tags: Letter to the Editor Source Type: research
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
This cohort study investigates differences in the effectiveness and treatment persistence between dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis who switched from natalizumab. (Source: JAMA Neurology)
Source: JAMA Neurology - June 5, 2023 Category: Neurology Source Type: research
EE143 Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile
To develop a cost-effectiveness analysis of ocrelizumab versus other first-line treatment alternatives (interferons, dimethyl fumarate, glatiramer acetate, teriflunomide, and fingolimod) for highly active relapsing-remitting multiple sclerosis from the perspective of the Chilean public health system. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: E. V ásquez, P. Lasalvia, M. Rozas, C. Gejman Source Type: research
CO63 Comparative Clinical Effectiveness of Monoclonal Antibodies for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
To evaluate the relative clinical effectiveness of five monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, rituximab, ublituximab) as first-line disease-modifying therapies (DMT) for relapsing forms of multiple sclerosis (MS); and to compare these treatments to placebo and oral DMTs (dimethyl fumarate, fingolimod, ozanimod, ponesimod, and teriflunomide). (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: D. Nikitin, G. Lin, A. McKenna, S. Herron-Smith, J. Campbell, F.O. Agboola Source Type: research
CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis
The efficacy and safety of natalizumab versus fingolimod for relapsing-remitting multiple sclerosis (RRMS) had conflicting results, according to data from various medical centers across the globe. Therefore, we performed a systematic review and meta-analysis of data from real-world evidence (RWE) studies to evaluate the efficacy and safety Parameters of Natalizumab Versus Fingolimod. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: Z. Almalki Source Type: research
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
Multiple sclerosis (MS) is a disabling autoimmune demyelinating disorder affecting young people and causing significant disability. In the last decade, different microRNA (miRNA) expression patterns have been ... (Source: Journal of Neuroinflammation)
Source: Journal of Neuroinflammation - May 30, 2023 Category: Neurology Authors: Alicia Gonzalez-Martinez, Rohit Patel, Brian C. Healy, Hrishikesh Lokhande, Anu Paul, Shrishti Saxena, Mariann Polgar-Turcsanyi, Howard L. Weiner and Tanuja Chitnis Tags: Research Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
